

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1                   1.       (Currently amended) A pharmaceutical preparation for the treatment of  
2 blood coagulation disorders containing at least one pro-protein of blood coagulation selected  
3 from the group consisting of factor VIII, von Willebrand factor (vWF) or factor V, and, in  
4 addition, a coagulation physiologically inert receptor binding competitor selected from the group  
5 consisting of receptor associated protein (RAP) ~~RAP~~, a RAP mutant, a RAP analogue and the  
6 combination of tissue type plasminogen activator (tPA) and aprotinin.

1                   2.       (Original) A preparation according to claim 1, characterized in that said  
2 pro-protein is derived from a biological material selected from the group consisting of human  
3 plasma, a plasma faction and a cell culture supernatant.

1                   3.       (Original) A preparation according to claim 1, characterized in that it is  
2 provided as a set comprising:  
3                   said pro-protein of blood coagulation; and  
4                   said receptor binding competitor.

1                   4.       (Original) A preparation according to claim 1, characterized in that said  
2 pro-protein of blood coagulation is factor VIII and said receptor binding competitor is a mixture  
3 of aprotinin and tPA.

1                   5.       (Original) A preparation according to claim 1, characterized in that said  
2 pro-protein of blood coagulation is vWF and said binding competitor is a mixture of aprotinin  
3 and tPA.

1                   6.       (Original) A combination preparation containing aprotinin and tPA for  
2 medical use.

1                   7.       (Original) A method of treating a patient suffering from phenotypic  
2   coagulation factor deficiency, comprising the step of administering a composition according to  
3   claim 1 to said patient.

1                   8.       (Original) The method according to claim 7, further comprising the step of  
2   selecting a patient who is vWF deficient.

1                   9.       (Cancelled)

1                   10.      (Original) The method of claim 7, wherein said receptor binding  
2   competitor is a mixture of aprotinin and tPA.

1                   11.      (Original) The method of claim 7, wherein said pro-protein is blood  
2   coagulation factor VIII.

                  12.      (Cancelled)